drugset / Trial / NCT00454298

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

NCT00454298

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.

Timeline

Start
2007-05
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator AGG-523 Small molecule 900 mg Oral
Comparator AGG-523 Small molecule 1800 mg Oral

Indications